Difference between revisions of "Team:Cornell/wetlab"
Line 26: | Line 26: | ||
</div> | </div> | ||
<div class="col-md-10" style="overflow:hidden"> | <div class="col-md-10" style="overflow:hidden"> | ||
− | <div class="row" > | + | <div class="row gray" > |
− | <div class="col-md-12 | + | <div class="col-md-12"> |
<h1 id = "Overview">Overview</h1> | <h1 id = "Overview">Overview</h1> | ||
flavocide is fishPHARM’s biodegradeable peptide treatment for BCWD. To create our optimal treatment system, we had to first determine the most effective EcnB peptide against <i>F. psychrophilum</i>, the causative agent of BCWD. Multiple isoforms of the polypeptide toxin exist, each of which is produced by a different species of bacterium in nature. Zone of Inhibition trials and growth assays were then conducted to decide which species of bacterium produced the most potent EcnB isoform. A variety of organisms cause disease through their very presence in the host organism. The exploitation of toxins similar to the system developed by our team this year could pave the way for a microbiological treatment protocol for a plethora of other infectious diseases. | flavocide is fishPHARM’s biodegradeable peptide treatment for BCWD. To create our optimal treatment system, we had to first determine the most effective EcnB peptide against <i>F. psychrophilum</i>, the causative agent of BCWD. Multiple isoforms of the polypeptide toxin exist, each of which is produced by a different species of bacterium in nature. Zone of Inhibition trials and growth assays were then conducted to decide which species of bacterium produced the most potent EcnB isoform. A variety of organisms cause disease through their very presence in the host organism. The exploitation of toxins similar to the system developed by our team this year could pave the way for a microbiological treatment protocol for a plethora of other infectious diseases. | ||
Line 38: | Line 38: | ||
<p>Our constructs have been summarized as follows: </p> | <p>Our constructs have been summarized as follows: </p> | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row" > | ||
<div class="col-md-6"> | <div class="col-md-6"> | ||
<b>EcnB only series</b>: These parts included a constitutive T7 promoter, a ribosome-binding site, the EcnB genes, a 6X Histidine tag to facilitate protein purification, and a terminator. | <b>EcnB only series</b>: These parts included a constitutive T7 promoter, a ribosome-binding site, the EcnB genes, a 6X Histidine tag to facilitate protein purification, and a terminator. | ||
Line 44: | Line 46: | ||
<div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/f/f5/Cornell_EcnB_Only.png"></div> | <div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/f/f5/Cornell_EcnB_Only.png"></div> | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row" > | ||
<div class="col-md-6"> | <div class="col-md-6"> | ||
<div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/6/65/Cornell_MBP_TEV_EcnB.png"></div> | <div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/6/65/Cornell_MBP_TEV_EcnB.png"></div> | ||
Line 50: | Line 54: | ||
<b>MBP-TEV-EcnB series</b>: These parts included a fusion protein called Maltose Binding Protein (MBP) for additional stability. They have included a constitutive T7 promoter, a ribosome-binding site, the MBP gene, the TEV protease cutsite gene, the EcnB gene, a 6X Histidine tag to facilitate protein purification, and a terminator. | <b>MBP-TEV-EcnB series</b>: These parts included a fusion protein called Maltose Binding Protein (MBP) for additional stability. They have included a constitutive T7 promoter, a ribosome-binding site, the MBP gene, the TEV protease cutsite gene, the EcnB gene, a 6X Histidine tag to facilitate protein purification, and a terminator. | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row" > | ||
<div class="col-md-12"> | <div class="col-md-12"> | ||
<b>EDA-GSG series</b>: These parts included a newly discovered fusion protein called KHG/KDPG adolase (EDA). Since EDA has never been characterized or BioBricked in iGEM’s history, we wanted to test it with a known endoglucanase called cel5a. The first BioBrick included a constitutive T7 promoter, a ribosome-binding site, the EDA gene, the GSG linker sequence, BamHI/NdeI restriction sites for modularity, a 6X Histidine tag to facilitate protein purification, and a terminator. The second BioBrick included a cel5a gene at the modular site | <b>EDA-GSG series</b>: These parts included a newly discovered fusion protein called KHG/KDPG adolase (EDA). Since EDA has never been characterized or BioBricked in iGEM’s history, we wanted to test it with a known endoglucanase called cel5a. The first BioBrick included a constitutive T7 promoter, a ribosome-binding site, the EDA gene, the GSG linker sequence, BamHI/NdeI restriction sites for modularity, a 6X Histidine tag to facilitate protein purification, and a terminator. The second BioBrick included a cel5a gene at the modular site | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row"> | ||
<div class="col-md-6"> | <div class="col-md-6"> | ||
<div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/b/b7/Cornell_EDA_GSG_cel.png"></div> | <div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/b/b7/Cornell_EDA_GSG_cel.png"></div> | ||
Line 59: | Line 67: | ||
<div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/6/6d/Cornell_EDA_GSG_no_cel.png"></div> | <div class="thumbnail"><img src=" https://static.igem.org/mediawiki/2015/6/6d/Cornell_EDA_GSG_no_cel.png"></div> | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row"> | ||
<div class="col-md-6"> | <div class="col-md-6"> | ||
<b>EcnA/EcnB</b>: This BioBrick was created because EcnA is known to be the antidote for EcnB. When they are synthesized together, they are expected to offset the properties of each other. This part included a constitutive T7 promoter, a ribosome-binding site, the EcnA gene, the TEV protease cutsite gene, the EcnB gene, BamHI/NdeI restriction sites for modularity, a 6X Histidine tag to facilitate protein purification, and a terminator. | <b>EcnA/EcnB</b>: This BioBrick was created because EcnA is known to be the antidote for EcnB. When they are synthesized together, they are expected to offset the properties of each other. This part included a constitutive T7 promoter, a ribosome-binding site, the EcnA gene, the TEV protease cutsite gene, the EcnB gene, BamHI/NdeI restriction sites for modularity, a 6X Histidine tag to facilitate protein purification, and a terminator. | ||
Line 71: | Line 81: | ||
BL21 is a cell strain commonly used with the T7 bacteriophage promoter system. In its chromosomal DNA is the T7 RNA polymerase gene, which can be regulated by arabinose induction and glucose inhibition of the araBAD promoter. This allows for efficient and high-level protein expression. Furthermore, the T7 Lysozyme gene in the pLysS plasmid is able to reduce basal expression by suppressing T7 RNA polymerase activity in uninduced cells [1]. | BL21 is a cell strain commonly used with the T7 bacteriophage promoter system. In its chromosomal DNA is the T7 RNA polymerase gene, which can be regulated by arabinose induction and glucose inhibition of the araBAD promoter. This allows for efficient and high-level protein expression. Furthermore, the T7 Lysozyme gene in the pLysS plasmid is able to reduce basal expression by suppressing T7 RNA polymerase activity in uninduced cells [1]. | ||
</div> | </div> | ||
+ | </div> | ||
+ | <div class="row" > | ||
<div class="col-md-12"> | <div class="col-md-12"> | ||
<h1 id = "isoforms">EcnB Isoform & Strain List</h1> | <h1 id = "isoforms">EcnB Isoform & Strain List</h1> | ||
Line 168: | Line 180: | ||
<i>Flavobacterium psychrophilum</i> is a non-model organism that no iGEM team has worked with before. We thus needed to modify our current bacterial culture techniques in order to successfully work with this novel bacterium. Thus, we collaborated with Dr. Rod Getchell of the Aquatic Animal Health Lab at Cornell’s College of Veterinary Medicine in order to fully realize our goals in characterizing <i>F. psychrophilum</i>. Dr. Getchell provided us with two strains of <i>F. psychrophilum</i> isolates (strain 025 and strain 431), recovered from the kidneys of systemically infected Chinook and Coho salmon in the Great Lakes. Below is our characterized growth curve of <i>F. psychrophilum</i> strain 025 and 431 in liquid cytophaga broth without the presence of EcnB peptide. | <i>Flavobacterium psychrophilum</i> is a non-model organism that no iGEM team has worked with before. We thus needed to modify our current bacterial culture techniques in order to successfully work with this novel bacterium. Thus, we collaborated with Dr. Rod Getchell of the Aquatic Animal Health Lab at Cornell’s College of Veterinary Medicine in order to fully realize our goals in characterizing <i>F. psychrophilum</i>. Dr. Getchell provided us with two strains of <i>F. psychrophilum</i> isolates (strain 025 and strain 431), recovered from the kidneys of systemically infected Chinook and Coho salmon in the Great Lakes. Below is our characterized growth curve of <i>F. psychrophilum</i> strain 025 and 431 in liquid cytophaga broth without the presence of EcnB peptide. | ||
</div> | </div> | ||
+ | <div class="row" > | ||
<div class="col-md-12"><img class="thumbnail center" src="https://static.igem.org/mediawiki/2015/2/2a/Cornell_Flavo_growth_graph.png"></div> | <div class="col-md-12"><img class="thumbnail center" src="https://static.igem.org/mediawiki/2015/2/2a/Cornell_Flavo_growth_graph.png"></div> | ||
</div> | </div> |
Revision as of 19:56, 18 September 2015